Risk factors for bacterial infections in HIV/hepatitis C virus-coinfected patients treated with interferon plus ribavirin.
Bani-Sadr
Firouzé
F
Goderel
Isabelle
I
Lapidus
Nathanael
N
Driss
Henda
H
Simon
Anne
A
Rosenthal
Eric
E
Morand
Patrice
P
Lunel-Fabiani
Françoise
F
Pol
Stanislas
S
Cacoub
Patrice
P
Perronne
Christian
C
Carrat
Fabrice
F
D000328:Adult; D000998:Antiviral Agents / Q000009:adverse effects*; D004359:Drug Therapy, Combination; D005260:Female; D015658:HIV Infections / Q000150:complications; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D009894:Opportunistic Infections / Q000139:chemically induced*; D011994:Recombinant Proteins; D012254:Ribavirin / Q000009:adverse effects*
D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D012254:Ribavirin